cbd oil cures brain cancer

Cbd oil cures brain cancer

“We hope this trial could pave the way for a long-awaited new lifeline that could help offer glioblastoma patients precious extra months to live and make memories with their loved ones,” said Dr David Jenkinson, the Brain Tumour Charity’s interim chief executive.

“The study was not designed to test whether Sativex was better in terms of survival. But it did suggest that some patients who had Sativex did better than expected and better than those who just had chemotherapy,” she said.

Sativex contains equal amounts of two cannabinoids: the psychoactive substance Delta-9-tetrahydrocannabinol (THC), which gives users a “high”, and cannabidiol (CBD), which can help reduce pain, inflammation and anxiety without inducing any psychoactive effects.

The Brain Tumour Charity, which is funding the trial, will recruit 232 patients early next year from at least 15 hospitals, including specialist cancer centres, across the UK. Two-thirds will receive Sativex and temozolomide while the other third will be given the chemotherapy drug and a placebo.

Short said that the initial study suggested that the drug could give some people some extra life. More participants who had Sativex were still alive a year later than those who had a placebo.

The Brain Tumour Charity plans to push ahead with the trial but stressed that doing so depended on the results of an appeal to help cover the £450,000 costs involved. It has suspended its usual programme of research grants after losing 25% of its income during the Covid-19 pandemic.

The trial follows an earlier study – a phase one trial – that looked purely at the safety of giving Sativex and temozolomide together, which involved 27 patients. The new three-year trial, called the Aristocrat study, will look at both the safety of that regime and what impact it has on the patient’s outcome, including how long they survive for.

See also  cbd clinic oil

Cbd oil cures brain cancer

Mr. Gross was scheduled to present this research at the American Society for Pharmacology and Experimental Therapeutics annual meeting in San Diego this month. Though the meeting, to be held in conjunction with the 2020 Experimental Biology conference, was canceled in response to the COVID-19 outbreak, the research team’s abstract was published in this month’s issue of The FASEB Journal.

“Further research and treatment options are urgently needed for patients afflicted by brain cancer,” said Chase Gross, a student in the Doctor of Veterinary Medicine/Master of Science program at Colorado State University. “Our work shows that CBD has the potential to provide an effective, synergistic glioblastoma therapy option and that it should continue to be vigorously studied.”

The researchers believe that CBD’s anti-cancer actions target mitochondria — the cell’s energy producing structures — by causing the mitochondria to dysfunction and release harmful reactive oxygen species. The mitochondria (teal color) in a canine cancer cell line are shown after 48 hours of treatment with a nonlethal dose of CBD isolate (40x objective lens). Credit: Chase Gross, Mando Ramirez, Jade Kurihara, Colorado State University

The new work revealed that the toxic effects of CBD are mediated through the cell’s natural pathway for apoptosis, a form of programmed cell death. The researchers also observed that CBD-induced cell death was characterized by large, swollen intracellular vesicles before the membrane begins to bulge and breakdown. This was true for all the cell lines studied.

A bright field microscopy image (10x) illustrating the swollen intracellular vesicles observed after 48 hours of treatment with a lethal dose of CBD (10x objective lens). Swollen vesicles were a hallmark of CBD-induced cell death in all the cell lines studied. Credit: Chase Gross, Mando Ramirez, Colorado State University

See also  can cbd be detected in a blood test

Cbd oil cures brain cancer

Participants will be asked to administer up to 12 sprays per day (or to the maximum dose they can tolerate if fewer than 12) of Sativex or placebo oral sprays.

A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumour is to launch at 15 NHS hospitals, following promising results from a phase I study in 27 patients.

“Glioblastoma brain tumours have been shown to have receptors to cannabinoids on their cell surfaces, and laboratory studies on glioblastoma cells have shown these drugs may slow tumour growth and work particularly well when used with temozolomide.

Having seen its income drop by more than 25% last year due to the pandemic and forced to pause its regular research grant funding programme, The Brain Tumour Charity has today launched an appeal to raise the £450,000 needed to open the trial as soon as possible.

‘Life beyond a glioblastoma diagnosis’

Participants will then undergo regular follow-up including clinical assessment (every four weeks), blood tests, MRI scans (every eight weeks), and they will complete quality of life questionnaires. This will also be one of the first trials to integrate with The Brain Tumour Charity’s app BRIAN.

The drug, already used in treating multiple sclerosis, was found to be tolerable in combination with chemotherapy, with the potential to extend survival, in a phase I trial in glioblastomas earlier this year.

“I took the oral spray 10 times a day, and it was easy as I could take it wherever we were going, even while out for dinner. While I don’t know whether I had Sativex or the placebo, since the trial finished in 2016, all my MRI scans have been clear.

See also  fedora 17 cbd content

Tackling aggressive brain cancer

“With so few treatments available and average survival still so heartbreakingly short, thousands affected by a glioblastoma in the UK each year are in urgent need of new options and new hope.

Sativex, manufactured by GW Pharma, is an oromucosal spray containing 1:1 THC (Delta-9-tetrahydrocannabinol) and CBD (cannabidiol), with the active ingredients being absorbed in the lining of the mouth, either under the tongue or inside the cheek.